M Capital

About M Capital

M Capital is a leading French private investment firm with over €635 million of assets under management, specialising in private equity, venture capital, real estate and private debt strategies. Founded over a decade ago and headquartered in Paris, the firm operates as a multi-strategy platform providing diversified French alternative investment exposure across distinct return profiles and asset classes.

Investment thesis

M Capital deploys across four complementary strategies: private equity (mid-cap LBO and growth), venture capital (early-stage), real estate (selective French positions) and private debt (mezzanine and unitranche financing). Sector focus across the PE strategy spans the broad coverage typical of multi-strategy platforms, with equity ticket sizes varying significantly by strategy from venture-stage early commitments through to mid-cap PE and dedicated real estate or debt positions.

Recent activity

The platform tracks 3 funds and 24 active portfolio companies across the multi-strategy programme. The diversified strategy mix enables ongoing capital deployment across multiple distinct return profiles depending on transaction structure and stage requirements.

Frequently asked questions

What investment strategy does M Capital focus on?

M Capital focuses on VC, Growth, Buyout strategies in the private equity space.

How many portfolio companies does M Capital have?

M Capital has 36 active portfolio companies and 7 completed exits and 4 funds tracked on GP Intel.

Where is M Capital headquartered?

M Capital is headquartered in PARIS, France.

What is M Capital's assets under management?

M Capital manages approximately €635M in assets under management.

When was M Capital founded?

M Capital was founded in 2018.

What sectors does M Capital invest in?

M Capital invests across Business Services, Consumer, Healthcare, Software, Industrials.

What are M Capital's recent exits?

Recent realized exits by M Capital include: SchoolMouv (2026) to Sofatutor; Robocath (2026) to Stereotaxis; VIMS (2024) to Zimmer Biomet; Cyclable (2022) to Calcium Capital; Avis Vérifiés (2019) to Providence Strategic Growth; Vexim (2017) to Stryker, 2.0x; Groupe Omega (2016) to Siparex Intermezzo and GSO Capital.